

Antonella Ravaggi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9413159/publications.pdf>

Version: 2024-02-01

121
papers

4,556
citations

76326

40
h-index

123424

61
g-index

122
all docs

122
docs citations

122
times ranked

6037
citing authors

#	ARTICLE	IF	CITATIONS
1	VEGF-D Serum Level as a Potential Predictor of Lymph Node Metastasis and Prognosis in Vulvar Squamous Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , 2022, 12, 818613.	2.8	1
2	<scp>L1CAM</scp> expression as a predictor of platinum response in high-risk endometrial carcinoma. <i>International Journal of Cancer</i> , 2022, 151, 637-648.	5.1	7
3	The Claudin-Low Subtype of High-Grade Serous Ovarian Carcinoma Exhibits Stem Cell Features. <i>Cancers</i> , 2021, 13, 906.	3.7	6
4	Integrated mutational landscape analysis of uterine leiomyosarcomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	48
5	Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial. <i>BMC Cancer</i> , 2021, 21, 561.	2.6	5
6	Gene Expression Profiling of Olfactory Neuroblastoma Helps Identify Prognostic Pathways and Define Potentially Therapeutic Targets. <i>Cancers</i> , 2021, 13, 2527.	3.7	17
7	Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes. <i>Frontiers in Immunology</i> , 2021, 12, 690201.	4.8	28
8	Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2021, 13, 3358.	3.7	9
9	Genome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma. <i>Theranostics</i> , 2021, 11, 2987-2999.	10.0	37
10	PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine. , 2021, 9, e002179.		6
11	Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1287.	2.8	9
12	964P Gene expression profiling to improve prognostic characterization of olfactory neuroblastoma and to define new targetable pathways. <i>Annals of Oncology</i> , 2020, 31, S680.	1.2	0
13	Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 584022.	2.8	6
14	Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer. <i>International Journal of Cancer</i> , 2020, 147, 565-574.	5.1	15
15	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22730-22736.	7.1	52
16	FXVD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients. <i>British Journal of Cancer</i> , 2019, 121, 584-592.	6.4	30
17	Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study. <i>Cells</i> , 2019, 8, 1554.	4.1	9
18	Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 619-624.	7.1	49

#	ARTICLE	IF	CITATIONS
19	Claudin3 is localized outside the tight junctions in human carcinomas. <i>Oncotarget</i> , 2018, 9, 18446-18453.	1.8	15
20	Utility of human epididymis protein 4 serum marker for the detection of adnexal malignancy: a multicentric prospective study. <i>European Journal of Cancer Prevention</i> , 2017, 26, 346-350.	1.3	7
21	FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 63.	8.6	53
22	Polymerase β (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. <i>Gynecologic Oncology</i> , 2017, 144, 146-152.	1.4	55
23	Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts. <i>Cancer Letters</i> , 2017, 388, 320-327.	7.2	73
24	RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients. <i>Scientific Reports</i> , 2017, 7, 10528.	3.3	19
25	Epidermal growth factor receptor detection in serum and saliva as a diagnostic and prognostic tool in oral cancer. <i>Laryngoscope</i> , 2017, 127, E408-E414.	2.0	29
26	MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis. <i>BMC Cancer</i> , 2017, 17, 366.	2.6	16
27	Kinase-driven metabolic signalling as a predictor of response to carboplatin+paclitaxel adjuvant treatment in advanced ovarian cancers. <i>British Journal of Cancer</i> , 2017, 117, 494-502.	6.4	10
28	lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study. <i>Clinical Cancer Research</i> , 2017, 23, 2356-2366.	7.0	57
29	Utility Serum Marker HE4 for the Differential Diagnosis Between Endometriosis and Adnexal Malignancy. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 52-55.	2.5	9
30	Identification of stably expressed reference small non-coding RNA for microRNA quantification in high-grade serous ovarian carcinoma tissues. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 2341-2348.	3.6	50
31	Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 61-69.	2.8	23
32	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12238-12243.	7.1	181
33	The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines. <i>Oncology Letters</i> , 2016, 12, 2493-2500.	1.8	14
34	A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment. <i>Annals of Oncology</i> , 2016, 27, 1511-1519.	1.2	20
35	HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study. <i>Gynecologic Oncology</i> , 2016, 141, 303-311.	1.4	87
36	Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study. <i>Annals of Oncology</i> , 2015, 26, 1363-1371.	1.2	37

#	ARTICLE	IF	CITATIONS
37	Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: Implications for personalized cancer therapy. <i>Proteomics</i> , 2015, 15, 365-373.	2.2	22
38	Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery. <i>Oncotarget</i> , 2015, 6, 34617-34628.	1.8	15
39	Identification of Optimal Reference Genes for Gene Expression Normalization in a Wide Cohort of Endometrioid Endometrial Carcinoma Tissues. <i>PLoS ONE</i> , 2014, 9, e113781.	2.5	29
40	Protein network mapping of glucose metabolism in ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5550-5550.	1.6	0
41	Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. <i>Journal of Translational Medicine</i> , 2013, 11, 162.	4.4	6
42	Class III β -tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 62.e1-62.e9.	1.3	26
43	Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2916-2921.	7.1	275
44	miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities. <i>Clinical Cancer Research</i> , 2013, 19, 4114-4123.	7.0	53
45	Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1815-24.	2.3	32
46	Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy. <i>British Journal of Cancer</i> , 2013, 109, 462-471.	6.4	24
47	Abstract B18: miRNA landscape analysis of stage I EOC, identifies miR-199a-5p associated to poor prognosis in grade 3 subgroup. , 2013, , .		0
48	Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer. <i>ISRN Obstetrics & Gynecology</i> , 2012, 2012, 1-11.	1.2	31
49	Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 2189-2198.	2.3	72
50	A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. <i>Oncogene</i> , 2012, 31, 4559-4566.	5.9	71
51	Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. <i>BMC Clinical Pathology</i> , 2012, 12, 22.	1.8	45
52	Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2496-2506.	2.5	112
53	HE4 and epithelial ovarian cancer: Comparison and clinical evaluation of two immunoassays and a combination algorithm. <i>Clinica Chimica Acta</i> , 2011, 412, 1447-1453.	1.1	104
54	Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma: Implications for Immunotherapy With hRS7, a Humanized Anti-Trop-2 Monoclonal Antibody. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1613-1621.	2.5	30

#	ARTICLE	IF	CITATIONS
55	Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. <i>British Journal of Cancer</i> , 2011, 104, 1418-1425.	6.4	134
56	Investigation of the Ovarian and Prostate Cancer Peptidome for Candidate Early Detection Markers Using a Novel Nanoparticle Biomarker Capture Technology. <i>AAPS Journal</i> , 2010, 12, 504-518.	4.4	51
57	Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. <i>European Journal of Cancer</i> , 2010, 46, 944-953.	2.8	94
58	Abstract 4584: Verification of ovarian cancer biomarker candidates by nanoparticle-capture MRM. , 2010, , .		0
59	Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence. <i>BMC Cancer</i> , 2009, 9, 253.	2.6	19
60	Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 201, 70.e1-70.e9.	1.3	24
61	Human Kallikrein 5: An Interesting Novel Biomarker in Ovarian Cancer Patients That Elicits Humoral Response. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1015-1021.	2.5	19
62	Serum S100A6 Concentration Predicts Peritoneal Tumor Burden in Mice with Epithelial Ovarian Cancer and Is Associated with Advanced Stage in Patients. <i>PLoS ONE</i> , 2009, 4, e7670.	2.5	38
63	Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. <i>British Journal of Cancer</i> , 2008, 99, 768-773.	6.4	40
64	Mammaglobin B expression in human endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 1090-1096.	2.5	27
65	Claudin-7 expression in human epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 1262-1271.	2.5	45
66	Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial. <i>Journal of Virology</i> , 2008, 82, 1968-1979.	3.4	124
67	Overexpression of mammaglobin B in epithelial ovarian carcinomas. <i>Gynecologic Oncology</i> , 2007, 105, 578-585.	1.4	28
68	Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 196, 245.e1-245.e11.	1.3	82
69	Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. <i>Archives of Virology</i> , 2006, 151, 1899-1916.	2.1	17
70	HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. <i>Gynecologic Oncology</i> , 2006, 100, 469-478.	1.4	90
71	Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy. <i>Gynecologic Oncology</i> , 2006, 103, 405-416.	1.4	104
72	Induction of tumour-specific CD8+ cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer. <i>British Journal of Cancer</i> , 2002, 86, 151-157.	6.4	31

#	ARTICLE	IF	CITATIONS
73	Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer. <i>Minerva Ginecologica</i> , 2002, 54, 133-44.	0.8	7
74	Phenotypic and Functional Analysis of Tumor-Infiltrating Lymphocytes Compared with Tumor-Associated Lymphocytes from Ascitic Fluid and Peripheral Blood Lymphocytes in Patients with Advanced Ovarian Cancer. <i>Gynecologic and Obstetric Investigation</i> , 2001, 51, 254-261.	1.6	72
75	Increased levels of interleukin-10 and transforming growth factor- β in the plasma and ascitic fluid of patients with advanced ovarian cancer. <i>British Journal of Obstetrics and Gynaecology</i> , 2001, 108, 804-808.	0.9	30
76	Tumor-Infiltrating Lymphocytes Contain Higher Numbers of Type 1 Cytokine Expressors and DR+ T Cells Compared with Lymphocytes from Tumor Draining Lymph Nodes and Peripheral Blood in Patients with Cancer of the Uterine Cervix. <i>Gynecologic Oncology</i> , 2001, 81, 424-432.	1.4	30
77	Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2001, 108, 804-808.	2.3	41
78	Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. <i>Clinical Cancer Research</i> , 2001, 7, 804s-810s.	7.0	22
79	Effects of concurrent cisplatin administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 997-1006.	0.8	84
80	In vitro induction of tumor-specific human lymphocyte antigen class II-restricted CD8+ cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2000, 183, 601-609.	1.3	44
81	Development and Therapeutic Effect of Adoptively Transferred T Cells Primed by Tumor Lysate-Pulsed Autologous Dendritic Cells in a Patient with Metastatic Endometrial Cancer. <i>Gynecologic and Obstetric Investigation</i> , 2000, 49, 194-203.	1.6	27
82	Induction of Ovarian Tumor-Specific CD8+ Cytotoxic T Lymphocytes by Acid-Eluted Peptide-Pulsed Autologous Dendritic Cells. <i>Obstetrics and Gynecology</i> , 2000, 96, 422-430.	2.4	2
83	Transduction and Utility of the Granulocyte-Macrophage Colony-Stimulating Factor Gene into Monocytes and Dendritic Cells by Adeno-Associated Virus. <i>Journal of Interferon and Cytokine Research</i> , 2000, 20, 21-30.	1.2	57
84	Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+ Cytotoxic T Lymphocytes. <i>Journal of Virology</i> , 2000, 74, 4729-4737.	3.4	137
85	Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. <i>Obstetrics and Gynecology</i> , 2000, 96, 422-430.	2.4	54
86	Development, characterization and distribution of adoptively transferred peripheral blood lymphocytes primed by human papillomavirus 18 E7-pulsed autologous dendritic cells in a patient with metastatic adenocarcinoma of the uterine cervix. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2000, 21, 17-23.	0.2	13
87	Influence of maternal CD4 levels on the predictive value of virus load over mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1). , 1999, 58, 59-62.		4
88	Expression of Surface Antigens During the Differentiation of Human Dendritic Cells vs Macrophages from Blood Monocytes in vitro. <i>Immunobiology</i> , 1999, 200, 187-204.	1.9	47
89	Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. <i>Obstetrics and Gynecology</i> , 1999, 94, 78-82.	2.4	18
90	Secretion of Vascular Endothelial Growth Factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix. <i>Obstetrics and Gynecology</i> , 1999, 94, 78-82.	2.4	8

#	ARTICLE	IF	CITATIONS
91	Induction of Human Papillomavirus-Specific CD4 ⁺ and CD8 ⁺ Lymphocytes by E7-Pulsed Autologous Dendritic Cells in Patients with Human Papillomavirus Type 16- and 18-Positive Cervical Cancer. <i>Journal of Virology</i> , 1999, 73, 5402-5410.	3.4	142
92	Effects of Retinoic Acid Combined with Irradiation on the Expression of Major Histocompatibility Complex Molecules and Adhesion/Costimulation Molecules ICAM-1 in Human Cervical Cancer. <i>Gynecologic Oncology</i> , 1998, 70, 195-201.	1.4	17
93	Retinoic acid up-regulates the expression of major histocompatibility complex molecules and adhesion/costimulation molecules (specifically, intercellular adhesion molecule ICAM-1) in human cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1998, 179, 1020-1025.	1.3	8
94	Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma. <i>Cancer</i> , 1998, 83, 2346-2352.	4.1	55
95	Effects of retinoic acid combined with interferon-gamma on the expression of major-histocompatibility-complex molecules and intercellular adhesion molecule-1 in human cervical cancer. , 1998, 75, 254-258.		10
96	Genetic evolution of the hypervariable region 1 in hepatitis C virus carriers with normal aminotransferase activities. <i>Research in Virology</i> , 1998, 149, 439-444.	0.7	0
97	The effects of irradiation on the expression of a tumour rejection antigen (heat shock protein gp96) in human cervical cancer. <i>International Journal of Radiation Biology</i> , 1998, 73, 699-704.	1.8	25
98	Effects of retinoic acid combined with interferon-gamma on the expression of a tumor rejection antigen (heat shock protein gp96) in human cervical cancer. <i>International Journal of Gynecological Cancer</i> , 1998, 8, 158-163.	2.5	2
99	Prospective study of mother-to-infant transmission of hepatitis C virus (HCV) infection. <i>Journal of Medical Virology</i> , 1998, 54, 12-19.	5.0	1
100	Outbreak of Hepatitis C Virus Infection in Patients With Hematologic Disorders Treated With Intravenous Immunoglobulins: Different Prognosis According to the Immune Status. <i>Blood</i> , 1997, 90, 1309-1314.	1.4	43
101	Comparison of competitive and non-competitive reverse transcription-polymerase chain reaction (RT-PCR) for the quantification of hepatitis C virus (HCV) RNA. <i>Journal of Virological Methods</i> , 1997, 65, 123-129.	2.1	7
102	Expression and cytokine mediated modulation of adhesion/costimulation molecules ICAM-1(CD54) and LFA-3(CD58) in human ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 1997, 7, 273-278.	2.5	1
103	Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients. <i>Hepatology</i> , 1997, 26, 792-797.	7.3	61
104	Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis. <i>Hepatology</i> , 1997, 26, 1012-1017.	7.3	44
105	Virological characterization and liver histology in HCV positive subjects with normal and elevated ALT levels. <i>Liver</i> , 1997, 17, 133-138.	0.1	23
106	Outbreak of Hepatitis C Virus Infection in Patients With Hematologic Disorders Treated With Intravenous Immunoglobulins: Different Prognosis According to the Immune Status. <i>Blood</i> , 1997, 90, 1309-1314.	1.4	8
107	Molecular analysis of mixed infection with hepatitis C virus and human immunodeficiency virus in a patient infected simultaneously. <i>Journal of Medical Virology</i> , 1996, 50, 276-282.	5.0	6
108	Hepatitis C virus genotypes in northern Italy: clinical and virological features. <i>Journal of Clinical Microbiology</i> , 1996, 34, 2822-2825.	3.9	20

#	ARTICLE	IF	CITATIONS
109	Long-term follow-up of and infectivity in blood donors with hepatitis C antibodies and persistently normal alanine aminotransferase levels. <i>Transfusion</i> , 1995, 35, 108-111.	1.6	17
110	Emergence of hepatitis B virus S gene mutant in a liver transplant recipient. <i>Journal of Medical Virology</i> , 1995, 47, 410-415.	5.0	37
111	Quantification of hepatitis C virus RNA by competitive amplification of RNA from denatured serum and hybridization on microtiter plates. <i>Journal of Clinical Microbiology</i> , 1995, 33, 265-269.	3.9	31
112	Intracellular localization of full-length and truncated hepatitis C virus core protein expressed in mammalian cells. <i>Journal of Hepatology</i> , 1994, 20, 833-836.	3.7	58
113	Differential pattern of sequence heterogeneity in the hepatitis C virus E1 and E2/NS1 proteins. <i>Journal of Hepatology</i> , 1994, 21, 858-865.	3.7	8
114	Diagnosis of viral hepatitis with a nonisotopic hybridization assay. <i>Nuclear Medicine and Biology</i> , 1994, 21, 441-447.	0.6	1
115	Clinical significance of serum hepatitis C virus (HCV) RNA as marker of HCV infection. <i>Journal of Clinical Microbiology</i> , 1994, 32, 3008-3012.	3.9	24
116	Distribution of viral genotypes in Italy determined by hepatitis C virus typing by DNA immunoassay. <i>Journal of Clinical Microbiology</i> , 1994, 32, 2280-2284.	3.9	29
117	Direct PCR amplification of HCV RNA from human serum.. <i>Genome Research</i> , 1992, 1, 291-292.	5.5	42
118	Evaluation of hepatitis delta virus RNA levels during interferon therapy by analysis of polymerase chain reaction products with a nonradioisotopic hybridization assay. <i>Hepatology</i> , 1992, 15, 685-689.	7.3	28
119	Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection. <i>Hepatology</i> , 1992, 16, 877-881.	7.3	105
120	Rapid screening of recombinant plasmids with a non-radioisotopic hybridization assay. <i>BioTechniques</i> , 1992, 13, 506-8.	1.8	0
121	Heterogeneity of the Hepatitis C Virus Genome. <i>Journal of Infectious Diseases</i> , 1991, 163, 1383-1384.	4.0	3